Table 3.
RBPs and their role in inflammation and hematological malignancies.
| RBP | Function | Role in Inflammation | Role in Hematological Malignancies | Clinical Implications | Drugs/Inhibitors | References |
|---|---|---|---|---|---|---|
| ZFP36 (TTP) | mRNA destabilization | Inhibits cytokine production (TNF-α, IL-6) |
Implicated in inflammation-induced cancer development and progression | Potential tumor suppressor; Restoration may impair lymphoma development | None specified | (271, 272) |
| HuR (ELAVL1) | mRNA stabilization | Increases stability of pro-inflammatory cytokine mRNAs | Associated with various cancers (e.g., breast, lung, ovarian) | Cytoplasmic expression correlates with tumor size and grade; Potential therapeutic target | HuR inhibitors (e.g., MS-444, H1N, Mitoxantrone, CMLD-2, Quercetin, dihydrotanshinone-I) | (223, 273) |
| IGF2BPs (1–3) | Regulate mRNA stability, translation, decay | Stabilize pro-inflammatory genes in JAK/STAT, ErbB pathways | Implicated in multiple cancers (e.g., B-ALL, breast, colon) | Overexpression linked to tumor-associated inflammation; Potential therapeutic targets | BTYNB, C20H18BrN5OS, Compound 7773, JX5, CWI 1-2 |
(274, 275) |
| RBM39 (CAPER) | Pre-mRNA splicing; NFκB activation | Regulates steroid hormone receptor-mediated transcription | Associated with multiple malignancies (e.g., TNBC, AML) | Higher expression in various cancers; Implication in NFκB activation | E7820 | (127, 276, 277) |